Abstract
The so-called “silver tsunami” is a metaphor that the individuals 65 and older represent the most rapidly growing segment of the Western world population.
Aging is an ongoing process that leads to the loss of functional reserve of multiple organ systems, increased susceptibility to stress, it is associated with increased prevalence of chronic disease, and functional dependence. Determined by a combination of genetic and environmental factors, this process is highly individualized and poorly reflected in chronologic age. The heterogeneity and the complexity of the older old population represent the main challenge to the treatment of cancer in those patients. We should discern "fit" elderly in whom standard cancer treatment appears to be comparable to a younger population and “unfit” or "frail" elderly, in which the risks of the treatment may overwhelm potential benefits.
There are many aspects that have to be assessed before treating an elderly patient, or before to choose the treatment itself. In our review we will try to explain and describe the meaning and the most important aspects related to the oldest old complex patients, and how to manage those patients.
Keywords: Cancer, elderly, oldest old, sarcopenia, fatigue, frailty, CGA.
Current Pharmaceutical Design
Title:Treating Cancer in Older and Oldest Old Patients
Volume: 21 Issue: 13
Author(s): G. Colloca, A. Corsonello, E. Marzetti, L. Balducci, F. Landi, M. Extermann, G. Scambia, M. Cesari, I. Carreca, S. Monfardini and R. Bernabei
Affiliation:
Keywords: Cancer, elderly, oldest old, sarcopenia, fatigue, frailty, CGA.
Abstract: The so-called “silver tsunami” is a metaphor that the individuals 65 and older represent the most rapidly growing segment of the Western world population.
Aging is an ongoing process that leads to the loss of functional reserve of multiple organ systems, increased susceptibility to stress, it is associated with increased prevalence of chronic disease, and functional dependence. Determined by a combination of genetic and environmental factors, this process is highly individualized and poorly reflected in chronologic age. The heterogeneity and the complexity of the older old population represent the main challenge to the treatment of cancer in those patients. We should discern "fit" elderly in whom standard cancer treatment appears to be comparable to a younger population and “unfit” or "frail" elderly, in which the risks of the treatment may overwhelm potential benefits.
There are many aspects that have to be assessed before treating an elderly patient, or before to choose the treatment itself. In our review we will try to explain and describe the meaning and the most important aspects related to the oldest old complex patients, and how to manage those patients.
Export Options
About this article
Cite this article as:
Colloca G., Corsonello A., Marzetti E., Balducci L., Landi F., Extermann M., Scambia G., Cesari M., Carreca I., Monfardini S. and Bernabei R., Treating Cancer in Older and Oldest Old Patients, Current Pharmaceutical Design 2015; 21 (13) . https://dx.doi.org/10.2174/1381612821666150130122536
DOI https://dx.doi.org/10.2174/1381612821666150130122536 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews Coumarins as Antioxidants
Current Medicinal Chemistry Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses
Current Drug Targets - CNS & Neurological Disorders Modulation of Rack-1/PKCβII Signalling By Soluble AβPPα in SH-SY5Y Cells
Current Alzheimer Research Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Anabolic Androgenic Steroids and Intracellular Calcium Signaling: A Mini Review on Mechanisms and Physiological Implications
Mini-Reviews in Medicinal Chemistry Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathogenesis and Clinical Features of Obesity and Insulin Resistance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) MicroRNA 21 Emerging Role in Diabetic Complications: A Critical Update
Current Diabetes Reviews The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets